- GlobeNewswire•6 days ago
--ChemoCentryx retains all rights in the United States and China; Vifor Pharma gains additional marketing rights in Asia, including Japan and Middle Eastern markets--. --ChemoCentryx to receive additional ...
- GlobeNewswire•last monthChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
MOUNTAIN VIEW, Calif., Jan. 20, 2017-- ChemoCentryx, Inc., today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology 2017 Gastrointestinal ...
- GlobeNewswire•last monthChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco
What: ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant ...
CCXI : Summary for ChemoCentryx, Inc. - Yahoo Finance
ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||5.30 x 100|
|Ask||8.27 x 1200|
|Day's Range||6.82 - 7.19|
|52 Week Range||1.92 - 9.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-7.30|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|